Press Release
Monday, September 15, 2014

Strides partners with Gilead Sciences Inc, to bring Hepatitis C cure to 91 developing countries.

- Licensing agreement with Gilead Sciences, Inc to for generic sofosbuvir and investigational single tablet regimen of ledipasvir/sofosbuvir
- Agreement to increase access to Hepatitis C treatments in developing countries

Bangalore, September 15, 2014: Strides Arcolab Limited today announced that Gilead Sciences Inc has licensed Strides to produce **generic sofosbuvir and investigational single tablet regimen of ledipasvir/sofosbuvir** for treatment of **chronic hepatitis C**, for distribution to 91 developing countries including India, Egypt & Indonesia which are high burden countries. Strides is one among 7 Companies in India who are licensed by Gilead Sciences Inc.

The countries within the agreement account for more than 100 million people living with hepatitis C globally representing 54% of the total globally infected population.

Under the licensing agreements, Strides receives a complete technology transfer of the Gilead manufacturing process for both API & finished product to enable scale up production as quickly as possible. Strides can also set its own prices for the generic product they produce, paying a royalty on sales to Gilead to support product registrations, medical education and training, safety monitoring and other business essential activities. The licenses also permit the manufacture of sofosbuvir or ledipasvir in combination with other chronic hepatitis C medicines.

Sofosbuvir was approved under the trade name Sovaldi® by the U.S. Food and Drug Administration (FDA) in December 2013 and by the European Commission in January 2014. The FDA and the European Medicines Agency are currently reviewing Gilead’s applications for a single tablet regimen of ledipasvir/sofosbuvir; it is an investigational agent and its safety and efficacy have not been established yet.
**About Strides Arcolab**

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical Company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products.

The Company has 5 manufacturing facilities presence in more than 75 countries in developed and emerging markets.

Additional information is available at the Company’s website at [www.stridesarco.com](http://www.stridesarco.com).

For further information, please contact:

<table>
<thead>
<tr>
<th>Strides</th>
<th>PR Consultancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mohan Kumar, CEO – Pharma +91 80 6784 0748</td>
<td>Weber Shandwick</td>
</tr>
<tr>
<td>Vikesh Kumar +91 80 6784 0827 Kannan. N: +91 98450 54745</td>
<td>Kaveri Mandanna: +91 90089 59697 <a href="mailto:Kmandanna@webershandwick.com">Kmandanna@webershandwick.com</a></td>
</tr>
<tr>
<td></td>
<td>Mahesh Nair: +91 98803 76648 <a href="mailto:MNair@webershandwick.com">MNair@webershandwick.com</a></td>
</tr>
</tbody>
</table>